Last reviewed · How we verify
B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
Approved treatments
- Kymriah · Novartis Pharmaceuticals Corporation
Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse patent landscape — cliff calendar, originator estates, attackable patents
- B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse treatment landscape brief
- B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse treatment updates RSS
Frequently asked questions about B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
What drugs treat B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse?
Tracked treatments include Kymriah.
What is the treatment for B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse?
Standard treatment for B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse includes Kymriah. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse patent cliff · B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse CI report
- Treatment: Kymriah · Novartis Pharmaceuticals Corporation
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing